William Blair Forecasts Incyte's Q1 Earnings (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY - Free Report) - William Blair issued their Q1 2025 earnings per share estimates for shares of Incyte in a report released on Monday, February 10th. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will earn $0.66 per share for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Incyte's current full-year earnings is $0.35 per share. William Blair also issued estimates for Incyte's Q2 2025 earnings at $1.06 EPS, Q3 2025 earnings at $1.22 EPS and Q4 2025 earnings at $1.24 EPS.

Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a negative return on equity of 0.63% and a net margin of 0.80%.

A number of other equities analysts also recently weighed in on INCY. StockNews.com downgraded shares of Incyte from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 12th. Wells Fargo & Company increased their target price on Incyte from $68.00 to $70.00 and gave the company an "equal weight" rating in a research note on Thursday, December 19th. Stifel Nicolaus increased their price target on shares of Incyte from $75.00 to $77.00 and gave the company a "hold" rating in a report on Monday, February 10th. JMP Securities reissued a "market perform" rating on shares of Incyte in a report on Tuesday, February 11th. Finally, Morgan Stanley upped their price objective on Incyte from $64.00 to $69.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $75.59.

Incyte Trading Up 0.6 %

Shares of Incyte stock traded up $0.41 during trading on Thursday, hitting $70.42. The stock had a trading volume of 1,882,071 shares, compared to its average volume of 1,255,658. The stock has a 50 day simple moving average of $71.26 and a 200 day simple moving average of $69.22. Incyte has a 1 year low of $50.35 and a 1 year high of $83.95. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $13.57 billion, a PE ratio of 503.04, a P/E/G ratio of 0.53 and a beta of 0.70.

Insiders Place Their Bets

In related news, EVP Vijay K. Iyengar sold 6,043 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $75.38, for a total transaction of $455,521.34. Following the completion of the sale, the executive vice president now owns 30,658 shares of the company's stock, valued at $2,311,000.04. This trade represents a 16.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven H. Stein sold 12,352 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total value of $897,866.88. Following the completion of the transaction, the executive vice president now directly owns 66,967 shares in the company, valued at $4,867,831.23. This trade represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 19,695 shares of company stock valued at $1,444,356 over the last 90 days. Insiders own 17.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Haverford Trust Co raised its position in Incyte by 1.8% in the 3rd quarter. Haverford Trust Co now owns 7,796 shares of the biopharmaceutical company's stock worth $515,000 after buying an additional 135 shares during the last quarter. Retirement Systems of Alabama grew its stake in shares of Incyte by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 34,620 shares of the biopharmaceutical company's stock worth $2,391,000 after acquiring an additional 139 shares during the period. Nissay Asset Management Corp Japan ADV grew its stake in shares of Incyte by 0.7% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 20,371 shares of the biopharmaceutical company's stock worth $1,410,000 after acquiring an additional 150 shares during the period. V Square Quantitative Management LLC raised its holdings in shares of Incyte by 4.1% during the third quarter. V Square Quantitative Management LLC now owns 3,963 shares of the biopharmaceutical company's stock valued at $262,000 after purchasing an additional 155 shares during the last quarter. Finally, Trust Point Inc. boosted its holdings in Incyte by 5.0% in the fourth quarter. Trust Point Inc. now owns 3,282 shares of the biopharmaceutical company's stock worth $227,000 after purchasing an additional 156 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company's stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.